GT Biopharma, Inc.GTBPNASDAQ
Loading
Debt Growth Under PressureDecelerating
Percentile Rank31
Year-over-Year Change
Year-over-year debt growth rate
Latest
0.00%
↓ 100% vs avg
Percentile
P31
Within normal range
Average
249.98%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | -100.00% |
| Q1 2024 | -48.28% |
| Q4 2023 | -36.96% |
| Q3 2023 | -23.33% |
| Q2 2023 | -18.37% |
| Q1 2023 | -15.52% |
| Q4 2022 | -12.12% |
| Q3 2022 | -11.21% |
| Q2 2022 | -9.72% |
| Q1 2022 | 696.77% |
| Q4 2021 | 0.00% |
| Q3 2021 | 0.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | -99.88% |
| Q4 2020 | 13.94% |
| Q3 2020 | 5.23% |
| Q2 2020 | 64.00% |
| Q1 2020 | 0.26% |
| Q4 2019 | 0.38% |
| Q3 2019 | 7.77% |
| Q2 2019 | 7.48% |
| Q1 2019 | 6.34% |
| Q4 2018 | 1.66% |
| Q3 2018 | 54.32% |
| Q2 2018 | 132.43% |
| Q1 2018 | 9458.06% |
| Q4 2017 | 0.00% |
| Q3 2017 | -99.75% |
| Q2 2017 | 5.32% |
| Q1 2017 | -5.00% |
| Q4 2016 | 9.94% |
| Q3 2016 | 6.51% |
| Q2 2016 | 0.21% |
| Q1 2016 | 8.54% |